Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Leukemia (8)
Blood Cancer Journal (6)
Nature Communications (1)
Nature Genetics (1)
Scientific Reports (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (12)
Correspondence (3)
Amendments and Corrections (1)
Reviews (1)

Subject Check one or more subjects to show results from those subjects only.

Anatomy
Biomarkers
Cancer
Cardiology
Diseases
Genetics
Health care
Immunology
Medical research
Risk factors

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–17 of 17 results

Advanced filters: Author: Heinz Gisslinger Clear advanced filters

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

Robert Kralovics and colleagues report that the JAK2^V617F somatic mutation that drives the development of chronic myeloproliferative neoplasms is associated with the presence of a specific inherited haplotype in JAK2.

Damla Olcaydu
Ashot Harutyunyan
Robert Kralovics
Research15 Mar 2009
Nature Genetics

Volume: 41, P: 450-454
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2^V617F suppression and event-free survival in polycythemia vera

Tiziano Barbui
Arianna Ghirardi
Alessandro Maria Vannucchi
ResearchOpen Access06 Aug 2025
Blood Cancer Journal

Volume: 15, P: 1-10
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Emmanuelle Verger
Juliette Soret-Dulphy
Jean-Jacques Kiladjian
ResearchOpen Access04 Oct 2018
Blood Cancer Journal

Volume: 8, P: 1-6
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

Heinz Gisslinger
Christoph Klade
Jean-Jacques Kiladjian
ResearchOpen Access26 Aug 2023
Leukemia

Volume: 37, P: 2129-2132
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Somatic mutations drive the clonal proliferation of myeloproliferative neoplasms. Here the authors conduct a genome-wide association study and identify germline variation at multiple loci associated with the development and disease phenotype of these cancers.

William Tapper
Amy V. Jones
Nicholas C.P. Cross
ResearchOpen Access07 Apr 2015
Nature Communications

Volume: 6, P: 1-11
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients

Tiziano Barbui
Alessandra Carobbio
Francesco Passamonti
ResearchOpen Access15 Dec 2023
Blood Cancer Journal

Volume: 13, P: 1-5
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data

Martin Schalling
Andreas Gleiss
Heinz Gisslinger
CorrespondenceOpen Access13 Dec 2017
Blood Cancer Journal

Volume: 7, P: 1-4
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Jean-Jacques Kiladjian
Christoph Klade
Heinz Gisslinger
ResearchOpen Access24 Feb 2022
Leukemia

Volume: 36, P: 1408-1411
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

H Gisslinger
G Jeryczynski
J Thiele
ResearchOpen Access29 Dec 2015
Leukemia

Volume: 30, P: 1126-1132
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Francisco Cervantes
David M. Ross
Haifa Kathrin Al-Ali
Amendments and Corrections02 Sept 2021
Leukemia

Volume: 35, P: 3626
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Onima Chowdhury
Jennifer O’Sullivan
James Vardiman
Research07 Aug 2020
Leukemia

Volume: 35, P: 1197-1202
Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance

R Königsberg
J Ackermann
J Drach
Research02 Nov 2000
Leukemia

Volume: 14, P: 1975-1979
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Francisco Cervantes
David M. Ross
Haifa Kathrin Al-Ali
ResearchOpen Access20 May 2021
Leukemia

Volume: 35, P: 3455-3465
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients

Noemi Pavo
Henrike Arfsten
Martin Hülsmann
ResearchOpen Access22 Feb 2019
Scientific Reports

Volume: 9, P: 1-8
Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET’

H Gisslinger
G Jeryczynski
J Thiele
CorrespondenceOpen Access29 Nov 2016
Leukemia

Volume: 31, P: 768-769
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach

Alessandra Carobbio
Alessandro Maria Vannucchi
Tiziano Barbui
CorrespondenceOpen Access28 Jul 2023
Blood Cancer Journal

Volume: 13, P: 1-3
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

Tiziano Barbui
Jürgen Thiele
Ayalew Tefferi
ReviewsOpen Access09 Feb 2018
Blood Cancer Journal

Volume: 8, P: 1-11

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

Search

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

Neutrophil-to-Lymphocyte ratio as surrogate for JAK2^V617F suppression and event-free survival in polycythemia vera

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients

Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET’

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

Search

Quick links